Overview

The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether treatment with Ranolazine will improve exercise capacity in patients with Heart Failure with preserved left ventricular ejection fraction, or HFPEF.
Phase:
N/A
Details
Lead Sponsor:
University of California, San Diego
Collaborator:
Gilead Sciences
Treatments:
Cytochrome P-450 CYP3A Inhibitors
Ranolazine